In an update on its ₹825 crore contract development and manufacturing mandate, Morepen Laboratories said it had completed the first commercial dispatch, valued at approximately ₹50 crore.
Sanjay Suri, Morepen Labs Managing Director, said, Limited, said, it was a step in its transition towards long-duration global manufacturing partnerships. “Our teams have worked closely with the customer through validation, manufacturing readiness and supply-chain planning. Having started execution of commercial supplies, we are focused on scaling up, expanding capacity and building a stronger CDMO (contract development and manufacturing organization) platform across additional customer and product opportunities.”
Morepen expects to scale the program further in the coming quarter, with additional supplies of approximately ₹225 crore expected during Q2 wFY2026-27, subject to customer schedules and regulatory/commercial requirements, it said.
“Total reactor capacity is expected to reach approximately 600 KL by the end of Q2, followed by further expansion toward 800 KL and 1,000 KL in subsequent phases,” it added.